.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

The Role of Factor Xa Inhibitors in the Management of CAD/PAD

Latest News

David Au, MD, MS: Lifestyle Interventions for Weight Loss in Obese Patients with COPD

Claims-Based Algorithm Identifies PAH 6 Months Prior to Diagnosis

Holly Keir, PhD: Changes in Microbiome Observed Following ICS Withdrawal in Patients with COPD

View More News

The Role of Factor Xa Inhibitors in the Management of CAD/PAD

EP. 1: Atherosclerosis and Atherothrombosis Pathophysiology

EP. 2: Clinical Guidelines for Atherosclerosis Management

EP. 3: Atherosclerosis: Risk Assessment and Referral

EP. 4: Atherosclerosis: Overview of CAD/PAD

EP. 5: Approaching Understandings of Antithrombotic Therapy

EP. 6: Chronic CAD/PAD Versus Acute Coronary Syndrome

EP. 7: ACS Management Following Dual Antiplatelet Therapy

EP. 8: Role of Atrial Fibrillation and Anticoagulants in ACS

EP. 9: Factor Xa Inhibitors: Clinical Trial Results in Atherosclerosis

EP. 10: Practical Implications of the COMPASS Trial in Chronic CAD/PAD

Latest News